187 related articles for article (PubMed ID: 38441243)
1. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Ghobrial IM; Gormley N; Kumar SK; Mateos MV; Bergsagel PL; Chesi M; Dhodapkar MV; Dispenzieri A; Fonseca R; Getz G; Kastritis E; Kristinsson SY; Martinez-Climent JA; Manier S; Marinac CR; Maura F; Morgan GJ; Davies FE; Nadeem O; Nuvolone M; Paiva B; O'Donnell E; Prosper F; Shah UA; Sklavenitis-Pistofidis R; Sperling AS; Vassiliou GS; Munshi NC; Castle PE; Anderson KC; San Miguel JF
Blood Cancer Discov; 2024 May; 5(3):146-152. PubMed ID: 38441243
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
Mohyuddin GR; Koehn K; Abdallah AO; W Sborov D; Rajkumar SV; Kumar S; McClune B
Am J Hematol; 2021 Jun; 96(6):690-697. PubMed ID: 33735453
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
5. Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit-risk assessment: the BRAINS study including expert workshop.
Totton N; Julious SA; Coates E; Hughes DA; Cook JA; Biggs K; Hewitt C; Day S; Cook A
Health Technol Assess; 2023 Oct; 27(20):1-58. PubMed ID: 37982521
[TBL] [Abstract][Full Text] [Related]
6. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Picot J; Cooper K; Bryant J; Clegg AJ
Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
[TBL] [Abstract][Full Text] [Related]
9. Time to first recurrence as a trial endpoint: time to change?
Mehra R
Card Electrophysiol Rev; 2003 Sep; 7(3):280-4. PubMed ID: 14739728
[TBL] [Abstract][Full Text] [Related]
10. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
11. The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov.
Barth P; Vale C; Chambers AB; Reagan JL
Future Oncol; 2018 Aug; 14(19):1965-1976. PubMed ID: 30019947
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.
Drayson MT; Bowcock S; Planche T; Iqbal G; Pratt G; Yong K; Wood J; Raynes K; Higgins H; Dawkins B; Meads D; Hulme CT; Whittaker AC; Hawkey P; Low E; Dunn JA
Health Technol Assess; 2019 Nov; 23(62):1-94. PubMed ID: 31690402
[TBL] [Abstract][Full Text] [Related]
13. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
14. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
Rajkumar SV; Harousseau JL; Durie B; Anderson KC; Dimopoulos M; Kyle R; Blade J; Richardson P; Orlowski R; Siegel D; Jagannath S; Facon T; Avet-Loiseau H; Lonial S; Palumbo A; Zonder J; Ludwig H; Vesole D; Sezer O; Munshi NC; San Miguel J;
Blood; 2011 May; 117(18):4691-5. PubMed ID: 21292775
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
16. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
17. Myeloma in the Real World: What Is Really Happening?
Bergin K; McQuilten Z; Moore E; Wood E; Spencer A
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):133-144.e1. PubMed ID: 28153487
[TBL] [Abstract][Full Text] [Related]
18. Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Persoon S; Kersten MJ; Chinapaw MJ; Buffart LM; Burghout H; Schep G; Brug J; Nollet F
BMC Cancer; 2010 Dec; 10():671. PubMed ID: 21134270
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in multiple myeloma.
Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
Cochrane Database Syst Rev; 2002; (3):CD003188. PubMed ID: 12137679
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates in multiple myeloma.
Djulbegovic B; Wheatley K; Ross J; Clark O; Bos G; Goldschmidt H; Cremer F; Alsina M; Glasmacher A
Cochrane Database Syst Rev; 2001; (4):CD003188. PubMed ID: 11687178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
